Total Debt to Capital: Oncternal Therapeutics, Inc. (ONCT)

The Oncternal Therapeutics (ONCT) price chart on the GURU.Markets platform demonstrates the fallout from the closure of primary studies and the collapse of the R&D center due to competitor superiority, while the individual debt-to-equity ratio stands at 0.02. The business previously relied on developing specific inhibitors to combat blood diseases, but the current strategy focuses on bringing biologics for the therapy of solid tumors and lymphomas to market.

To protect the portfolio, fundamental screening utilizes the 0.02 ratio, which compares total liabilities to equity to assess the degree of credit leverage. In the case of Oncternal Therapeutics (ONCT), which is seeking ways to monetize patents ahead of a potential liquidation, the company's debt-to-equity ratio becomes a critical indicator of solvency in the absence of new investments in clinical development.